Dolutegravir, Trii and new abacavir data- How it all ties together
By Nelson Vergel Powerusa.org Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort 1) of patients who took …
Dolutegravir, Trii and new abacavir data- How it all ties together Read More »